Avant Diagnostics Announces Confirmatory Clinical Utility Data for Theralink® in Pancreatic Cancer GAITHERSBURG, Maryland, June 27, 2017 /PRNewswire/ -- - Theralink predicts 5-year survival for patients in response to standard of care - Negative predictive value allows physicians to change treatment decisions http://www.prnewswire.com/news-releases/avant-diagnostics-announces-confirmatory-clinical-utility-data-for-theralink-in-pancreatic-cancer-631044313.html